APA (7th ed.) Citation

Schmitz-Winnenthal, F. H., Hohmann, N., Friedrich, T., Mikus, G., Weitz, J., Ulrich, A., . . . Beckhove, P. (2015). Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. OncoImmunology, 4(4), . https://doi.org/10.1080/2162402X.2014.1001217

Chicago Style (17th ed.) Citation

Schmitz-Winnenthal, Friedrich Hubertus, et al. "Anti-angiogenic Activity of VXM01, an Oral T-cell Vaccine Against VEGF Receptor 2, in Patients with Advanced Pancreatic Cancer: A Randomized, Placebo-controlled, Phase 1 Trial." OncoImmunology 4, no. 4 (2015). https://doi.org/10.1080/2162402X.2014.1001217.

MLA (9th ed.) Citation

Schmitz-Winnenthal, Friedrich Hubertus, et al. "Anti-angiogenic Activity of VXM01, an Oral T-cell Vaccine Against VEGF Receptor 2, in Patients with Advanced Pancreatic Cancer: A Randomized, Placebo-controlled, Phase 1 Trial." OncoImmunology, vol. 4, no. 4, 2015, https://doi.org/10.1080/2162402X.2014.1001217.